Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Toripalimab in PD-L1 positive Triple Negative Breast Cancer: NCT07040644 Clinical Landscape Report 2026
28 September 2026
NCT07040644 clinical landscape for PD-L1 positive Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Sacituzumab govitecan-hziy in Advanced Triple-Negative Breast Carcinoma: NCT07046455 Clinical Landscape Report 2026
28 September 2026
NCT07046455 clinical landscape for Advanced Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Sacituzumab tirumotecan in Triple Negative Breast Cancer: NCT07054242 Clinical Landscape Report 2026
28 September 2026
NCT07054242 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fluzoparib in Glioblastoma, IDH-Wildtype: NCT07047066 Clinical Landscape Report 2026
28 September 2026
NCT07047066 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Birelentinib in Diffuse Large B-Cell Lymphoma: NCT07059650 Clinical Landscape Report 2026
28 September 2026
NCT07059650 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Imipramine Hydrochloride in Recurrent Glioma: NCT07074756 Clinical Landscape Report 2026
28 September 2026
NCT07074756 clinical landscape for Recurrent Glioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carboplatin in Neoplasm Metastasis: NCT07046923 Clinical Landscape Report 2026
28 September 2026
NCT07046923 clinical landscape for Neoplasm Metastasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pegfilgrastim (Amgen) in Ovarian Cancer: NCT07064018 Clinical Landscape Report 2026
28 September 2026
NCT07064018 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
68Ga/64Cu-FAPI-XT117 in Glioblastoma: NCT07067905 Clinical Landscape Report 2026
28 September 2026
NCT07067905 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anbalcabtagene autoleucel in Refractory Central Nervous System Lymphoma: NCT07062627 Clinical Landscape Report 2026
28 September 2026
NCT07062627 clinical landscape for Refractory Central Nervous System Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Ferumoxytol in Diffuse Large B-Cell Lymphoma: NCT07066436 Clinical Landscape Report 2026
28 September 2026
NCT07066436 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Datopotamab Deruxtecan in Residual Neoplasm: NCT07069595 Clinical Landscape Report 2026
28 September 2026
NCT07069595 clinical landscape for Residual Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white space.